HBK Investments’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

HBK Investments’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-117,680	Closed	-$6.36M	–	1199
2017 Q3	$6.36M	Buy	117,680 +19,180	+19%	+$1.13M	0.04%	225
2017 Q2	$5.53M	Buy	+98,500	New	+$3.95M	0.03%	227
2016 Q3	–	Sell	-50,994	Closed	-$1.2M	–	1075
2016 Q2	$1.2M	Sell	50,994 -33,216	-39%	-$820K	0.01%	526
2016 Q1	$1.72M	Buy	84,210 +34,310	+69%	+$1.09M	0.02%	467
2015 Q4	$2.57M	Buy	49,900 +34,200	+218%	+$1.66M	0.02%	356
2015 Q3	$669K	Buy	15,700 +8,700	+124%	+$420K	0.01%	681
2015 Q2	$319K	Sell	7,000 -31,319	-82%	-$1.26M	﹤0.01%	811
2015 Q1	$1.46M	Buy	+38,319	New	+$1.32M	0.01%	475
2014 Q3	–	Sell	-19,100	Closed	-$557K	–	1128
2014 Q2	$557K	Buy	+19,100	New	+$462K	0.01%	662

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

HBK Investments's PTLA Position: Q4 2017 in Review

HBK Investments sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2017, closing a stake of 117,680 shares — an estimated $6.36M sold.

HBK Investments first reported a position in PTLA in Q2 2014 and held it in 9 quarters. The position peaked at $6.36M in Q3 2017. 215 funds tracked by Wall St. Rank hold PTLA as of Q4 2017.

HBK Investments reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
HBK Investments sold 117,680 Portola Pharmaceuticals, Inc. shares in Q4 2017, an estimated $6.36M.
HBK Investments first reported a position in Portola Pharmaceuticals, Inc. in Q2 2014 and held it in 9 quarters.
HBK Investments's Portola Pharmaceuticals, Inc. position peaked at $6.36M in Q3 2017.
215 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2017.

Based on HBK Investments's 13F filing for Q4 2017, filed 14 Feb 2018.